Shares of Catalent Inc (NYSE:CTLT), which manufactures Elevidys, are trading higher with a strong session volume of 3.6 million compared to an average volume of 1.6 million. Also Read: Catalent’s Bloomington Plant Making Novo Nordisk’s Obesity Drug Faces FDA Scrutiny Regarding Drug Manufacturing Concerns. William Blair notes that Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) Elevidys, supported by its expanded label, is expected to generate approximately $700 million annually in revenue for fiscal years 2025 and 2026, representing a substantial increase from the approximately $425 million generated in fiscal year 2023. In October 2023, William Blair wrote that in fiscal ...